Company Filing History:

7 out of 504

Miles Laboratories, Inc.

patents

6 out of 68

Cutter Laboratories, Inc.

Years Active: 1982-1995

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5419906 - Preparation of human immunoglobulin free of hepatitis C (1995-05-30),

2. 5159064 - Preparation of virus-free antibodies (1992-10-27),

3. 5157113 - Removal of nucleic acids from monoclonal antibody preparations (1992-10-20),

4. 5115101 - Removal of protein A from antibody preparations (1992-05-19),

5. 5006472 - Enzymatic purification process (1991-04-09),

6. 4983722 - Removal of protein A from antibody preparations (1991-01-08),

7. 4948877 - Preparation of retrovirus-free immunoglobulins (1990-08-14),

8. 4762714 - Preparation of retrovirus-free immunoglobulins (1988-08-09),

9. 4689323 - Covalently bound heparin--antithrombin-III complex (1987-08-25),

10. 4684723 - Method of separating proteins from aqueous solutions (1987-08-04),

11. 4543210 - Process for producing a high purity antihemophilic factor concentrate (1985-09-24),

12. 4496689 - Covalently attached complex of alpha-1-proteinase inhibitor with a water (1985-01-29),

13. 4470968 - Pasteurized therapeutically active blood coagulation factor concentrates (1984-09-11),

14. 4455301 - Antihemophilic factor concentrate (1984-06-19),

15. 4404132 - Blood coagulation promoting product (1983-09-13),

Title: Innovations in Immunology: The Contributions of Gautam Mitra

Introduction: Gautam Mitra, based in Kensington, CA, has made significant strides in the field of immunology through his innovative inventions and research. With a remarkable portfolio of 19 patents, he has focused on the preparation of human immunoglobulins and the inactivation of viruses, with particular attention to the AIDS retrovirus.

Latest Patents: Mitra's latest patents showcase breakthrough methods in the preparation of human immunoglobulins free of hepatitis C and other retroviruses. One of his notable inventions details a method that results in a substantial reduction of the LAV strain of the AIDS retrovirus during the cold alcohol fractionation process. Achieving at least a 100,000-fold reduction in viral titer, Mitra demonstrated that adjustments to pH and temperature can effectively inactivate retroviruses. His research supports the clinical evidence that therapeutically processed immunoglobulins can be safe from retroviral transmission, thereby enhancing their therapeutic utility. Furthermore, the development of virus-free antibodies, including monoclonal antibodies, further emphasizes his innovative work in ensuring the safety and efficacy of immunological treatments.

Career Highlights: Throughout his career, Gautam Mitra has contributed to renowned companies in the biomedical field, including Miles Laboratories, Inc. and Cutter Laboratories, Inc. His expertise has been pivotal in advancing methods for viral inactivation and the preparation of safe immunological products.

Collaborations: Mitra's collaborations with esteemed colleagues such as Milton M. Mozen and George B. Dove have enriched his research endeavors. Their collective expertise and innovative spirit have propelled advancements in the production of safe and effective immunoglobulin therapies.

Conclusion: Gautam Mitra's contributions to immunology and patent innovations have significantly influenced the medical landscape. His focus on the safety and efficacy of immunological treatments has provided crucial advancements that not only protect patients from viral infections but also enhance the overall therapeutic effectiveness of immunoglobulins. Mitra stands as a leading inventor, showcasing the importance of innovation in the fight against infectious diseases.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com